Eli Lilly picks up another Covid-19 EUA as regulators wave through its Olumiant plus remdesivir combo
Eli Lilly has picked up another win at the FDA, crossing the finish line again in the Covid-19 treatment race despite some mixed data. And …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.